{"id":"bemotrizinol-6","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation"},{"rate":null,"effect":"Contact dermatitis"},{"rate":null,"effect":"Photosensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL2104956","moleculeType":"Small molecule","molecularWeight":"627.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bemotrizinol is a broad-spectrum organic UV absorber that protects against both UVA and UVB radiation by absorbing photons and dissipating the energy as heat. It is formulated as a topical sunscreen agent and is used in dermatological and cosmetic products to prevent photoaging and reduce skin cancer risk.","oneSentence":"Bemotrizinol is a UV filter that absorbs ultraviolet radiation to protect skin from sun damage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:57.714Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"UV protection and photoprotection in topical sunscreen formulations"}]},"trialDetails":[{"nctId":"NCT05277376","phase":"PHASE3","title":"Pharmacokinetic (PK) Evaluation of Bemotrizinol (6%) in a Sunscreen Maximum Usage Trial","status":"COMPLETED","sponsor":"dsm-firmenich Switzerland AG","startDate":"2022-03-15","conditions":"Pharmacokinetics, Absorption; Chemicals","enrollment":162},{"nctId":"NCT05260359","phase":"PHASE2","title":"Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol","status":"COMPLETED","sponsor":"dsm-firmenich Switzerland AG","startDate":"2022-02-23","conditions":"Sunburn","enrollment":224},{"nctId":"NCT05254925","phase":"PHASE2","title":"Phototoxicity Potential of 6% Bemotrizinol","status":"COMPLETED","sponsor":"dsm-firmenich Switzerland AG","startDate":"2022-02-28","conditions":"Phototoxic Response","enrollment":34},{"nctId":"NCT05254912","phase":"PHASE2","title":"Photoallergic Potential of 6% Bemotrizinol","status":"COMPLETED","sponsor":"dsm-firmenich Switzerland AG","startDate":"2022-03-07","conditions":"Photoallergic Response","enrollment":50},{"nctId":"NCT04355286","phase":"PHASE1","title":"Bemotrizinol UV Filter Part 1 Clinical PK Evaluation in Topical MUsT Study","status":"COMPLETED","sponsor":"dsm-firmenich Switzerland AG","startDate":"2020-11-03","conditions":"Absorption; Chemicals, Sunscreening Agents","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PARSOL SHIELD","BEMT","bis-ethylhexyloxyphenol methoxyphenyl triazine"],"phase":"phase_3","status":"active","brandName":"Bemotrizinol (6%)","genericName":"Bemotrizinol (6%)","companyName":"dsm-firmenich Switzerland AG","companyId":"dsm-firmenich-switzerland-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bemotrizinol, a sunscreening agent, has been studied in clinical trials for its potential to prevent photoallergic response, absorption, phototoxic response, and sunburn. The trials involved testing 6% Bemotrizinol in sunscreen formulations and petrolatum to evaluate its safety and efficacy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}